Lilly drug reduces blindness in diabetic patients
14th Nov 2006, 11:48 GMT
Eli Lilly has said results from a three-year phase III clinical trial suggested its experimental drug Arxxant reduced the risk of vision loss by 40% in patients with diabetic retinopathy.
Lilly drug reduces blindness in diabetic patients related news:
- Lilly Drug Reduces Blindness in Diabetic Patients — RedOrbit News - Health
- Lilly: Arxxant cuts sight loss in diabetes — United Press International - Health Business
- Study Favors TAXUS Stent Over Cypher Stent and Bare-Metal Stents in Diabetic Patients — Nephrology/ Dialysis News from StratCenter.com
- Enzyme May Hold Key To New Treatment Of Diabetic Kidney Disease — ScienceDaily Headlines: Health & Medicine
- November 8, 2006: In the News — Medscape Headlines
- FDA Proposes 'Abnormal Behavior' Warning for Tamiflu — KLTV - Local and National News
- Goat Riders of the Apocalypse :: Goat Riders: Hot Stove: Cubs contact Lilly, interested in Soriano — Sports Blogs :: Chicago Cubs Daily Entries
- Late angioplasty after heart attack no better than drug therapy — EurekAlert! - Breaking News
- Doctors Rarely Discuss Drug Costs With Patients — KeepMedia: KeepMedia Home
- FDA Orders Caution Over the use of Tamiflu — NPR Topics: Nation
Latest news from Pharmaceutical Business Review Latest News:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol